Maria Fardis
Executive Chairman of the BoardDr. Maria Fardis, MBA, Ph.D., is Chief Executive Officer, Chief Financial Officer & Secretary of AirNexis Therapeutics. Dr. Fardis is a Director of Obsidian Therapeutics, Inc. Dr. Fardis is Independent Director of CRISPR Therapeutics AG from June 09, 2022. Dr. Fardis is Executive Chairman of the Board of Obsidian Therapeutics, Inc. from January 2023 and its Director from October 2021. Dr. Fardis previously served as the Chief Operating Officer of Acerta Pharma B.V. from 2015 to 2016 and as a member of its board of directors from June 2016 to June 2021. Dr. Fardis was Chairman of the Board of Obsidian Therapeutics, Inc. from January 2022 to January 2023. Dr. Fardis is Board Chair of Lassen Therapeutics 1, Inc. since January 2023 and has been its CEO since May 2023 and serves as its CFO & Secretary. Dr. Fardis is Director of Quanta Therapeutics, Inc. Dr. Fardis is Venture Partner of Frazier Life Sciences Management, LP. Dr. Fardis joined the Frazier Life Sciences Management, LP in 2021. Dr. Fardis is Venture Partner of Frazier Management, L.L.C. from September 2021. Dr. Fardis joined the Frazier Management, L.L.C. in 2021. Dr. Fardis focuses on Life Sciences. Dr. Fardis was Chief of Oncology Operations & Alliances of Pharmacyclics LLC from 2011 to 2014. Dr. Fardis was CEO, President & Director of Iovance Biotherapeutics, Inc. from June 07, 2016 to May 2021. Dr. Fardis was employed at Iovance Biotherapeutics, Inc. from June 01, 2016 to May 2021. Dr. Fardis has Ph.D. in Organic Chemistry from University of California Berkeley, M.B.A. from Golden Gate University, B.S. in Chemistry from University of Illinois-Urbana-Champaign.
Positions
- Company NameObsidian Therapeutics, Inc.Stock CodeOBXPositionExecutive Chairman of the Board
